- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 8th, 2007
Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National Cancer Institute (NCI).
The Florida-based company will use its proprietary NanoDRY drug delivery technology to develop the peptide vaccine candidate into an oral form which will have targeted delivery to the lower gastrointestinal (GI) tract.
|Related News Press|
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
A nano-roundabout for light December 10th, 2016
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016